NewsBenzingaCullinan Therapeutics获得美国FDA和澳大利亚治疗用品管理局批准,启动其针对复发性和难治性ITP及温抗体自身免疫性溶血性贫血成人患者的全球1b/2a期临床试验 Cullinan Therapeutics获得美国FDA和澳大利亚治疗用品管理局批准,启动其针对复发性和难治性ITP及温抗体自身免疫性溶血性贫血成人患者的全球1b/2a期临床试验 Benzinga 2026.10.27 11:09 (GMT+0) Open on Benzinga Other news AI models can be tricked into identifying civilians as military targets by telling them it’s a game Why Nvidia Is Falling Tuesday: Jensen Huang’s Comeback Statement, Congress Hearings, and AI Risks General Motors Plans 20% Boost In Robotics As Factory Costs Rise Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer Therapies McKesson Stock Is a Triple Threat at New All-Time Highs. How to Trade It Here. 'Nvidia stopped disclosing Singapore sales as revenues hit $104B' -FT